GHIT Fund - Product Development Partnerships Webinar Series:

Contribution for Global Healthfrom Mitsubishi Tanabe Pharma Corp.
Sep. 3rd Friday 2021

KANO Hiroki
Mitsubishi Tanabe Pharma Corp.

Confidential

Mitsubishi Tanabe Pharma Crop.

Materiality that contributes to SDGs

https://www.mt-pharma.co.jp/e/sustainability/materiality.html
Confidential

2

Mitsubishi Tanabe Pharma Crop.

New MISSION

Creating hope for all facing illness.

Confidential

3

Mitsubishi Tanabe Pharma Crop.

Solving Issues Related to Improving Access to Healthcare

https://www.mt-pharma.co.jp/e/sustainability/social/medical_access.html
Confidential

4Overview• Malaria : Collaboration with••••2014 : HTS
2016 : Hit to Lead2019 : Lead Optimization (“Product Development Platform”)
Ongoing: Toward the Creation of Preclinical Candidates• Tuberculosis : Collaboration with• 2015 : HTS• Terminated : Unsuccessful to obtain promising HIT compounds• NTDs : Collaboration with• 2019 : HTS• 2021 : Hit to Lead (“Hit to Lead Platform”)• Ongoing: Toward the Creation of Early Lead
Confidential

5MalariaContributions• Overall management of projects• Progress management of CROs andacademia•

Synthesis of New Compound•

Bio-assays••

in vitro•

ADMET•

in vivo•

PK/PD

MOA analysis•

MaLDA Consortium Network• Screening Compound Library• Computational Chemistry•

SBDD• Analytical Chemistry
DrugDesign••Absolute Configuration Determination (X-rayCrystallography)•

Chiral Resolution Screening

Genotoxic Assessment•

Genotoxic Risk Prediction Calculation•

Micro Ames (“FAT Assay”)•

Full Ames

Confidential

6Malaria

Global Collaboration Network**Tokyo, Japan (Funding)Penn., USA(MOA)

Scotland, UK(Protein-X assay)
London, UK(DGFA assay)*Cambridge, USA(MOA)
Geneva, Swiss (PJ cordinate)*

San Diego, USA(Pb liver assay)

Basel, Swiss (MoA, in vivo)*
Sao Paulo, BZ(ex vivo)

Tres Cantos, Spain(in vivo, rate of killing)

Derio, Spain (in vivo)

West Bengal, India (Chemistry)

Melbourne, Australia (DMPK)

Brisbane, Australia(HTS, in vitro assays)* : MalDA (the Malaria Drug Accelarator) Consortium Member

Confidential

7

MTPC Screening Library• Size : 51.2k
MW

CLogP

RotB

TPSA

Fsp3*

CNS-MPO*** Lovering, F. et. al., J. Med. Chem., 2009, 52(21), 6752-6756.
** Wager, T. T., et. al. ACS. Chem. Nurosci., 2010, 1(6), 435-449.

Confidential

8

NTDs

Outline of Collaboration with DNDi
• Target : NTDs (Chagas disease / Leishmaniasis)• Current Status : 9 chemotypes Hit Series from MTPC Screening Collection• “Chagas Selective” and “Chagas/Leishmaniasis Dual”• Objective : Selection of promising hit series• Overall management of projects• Progress management of CROs
and academia

DrugDesign• Screening Compound Library• SAR Analysis for Preliminary Hit Series
SelectionConfidential

9Acknowledgement
Mitsubishi Tanabe Pharma Corp.

Medicines for Malaria Venture

Drugs for Neglected Disease Initiative

Dr. KAMIYAMA Tsutomu

Dr. Robert Jacobs

Dr. Jean-Robert Ioset

Dr. TORIMOTO-KATORI Nao

Dr. Stephen Brand

Dr. Peter Sjö

Dr. OKADA Okimasa

Ms. Delphine Baud

Mr. Leela Pavan Tadoori

Dr. ONO Satoshi

Dr. Benjamin Blasco

Mr. KUZUKI Tatsuro

Ms. NABENO Mika

Dr. James Duffy

Ms. MORIOKA Midori

Ms. TAHARA Saori

Monash University

Ms. UEDA Naoko

Prof. Susan Sharman

Ms. TANIGUCHI Tomomi

Dr. Karen WhiteMr. TSUDA Naoki
Dr. TAKANO Ryo
Dr. MUTO Shigeharu
Dr. YAMADA Katsuya

INSTITUT PASTEUR KOREA
Dr. David Shum

Griffith University
Prof. Vicky Avery
Dr. Leonardo Lucantoni

TB Alliance
Dr. KANEKO Takushi

Ms. FURUKAW Ayaka
Mr. KAJI Takahide
Mr. AOYAMA Yukio

All Financial Support from GHIT Fund
Confidential

10Confidential